CoChat

Gut Microbiome Wellness Index 2 enhances health status prediction from gut microbiome taxonomic profiles

Open access

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Recent advancements in translational gut microbiome research have revealed its crucial role in shaping predictive healthcare applications. Herein, we introduce the Gut Microbiome Wellness Index 2 (GMWI2), an enhanced version of our original GMWI prototype, designed as a standardized disease-agnostic health status indicator based on gut microbiome taxonomic profiles. Our analysis involves pooling existing 8069 stool shotgun metagenomes from 54 published studies across a global demographic landscape (spanning 26 countries and six continents) to identify gut taxonomic signals linked to disease presence or absence. GMWI2 achieves a cross-validation balanced accuracy of 80% in distinguishing healthy (no disease) from non-healthy (diseased) individuals and surpasses 90% accuracy for samples with higher confidence (i.e., outside the "reject option"). This performance exceeds that of the original GMWI model and traditional species-level α-diversity indices, indicating a more robust gut microbiome signature for differentiating between healthy and non-healthy phenotypes across multiple diseases. When assessed through inter-study validation and external validation cohorts, GMWI2 maintains an average accuracy of nearly 75%. Furthermore, by reevaluating previously published datasets, GMWI2 offers new insights into the effects of diet, antibiotic exposure, and fecal microbiota transplantation on gut health. Available as an open-source command-line tool, GMWI2 represents a timely, pivotal resource for evaluating health using an individual's unique gut microbial composition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-024-51651-9

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Conducting a pooled analysis of stool metagenomes across multiple health and disease conditions from a diverse global representation. a A survey was conducted in PubMed and Google Scholar to search for published studies with publicly available human stool shotgun metagenome (gut microbiome) samples from healthy (disease-free) and non-healthy (diseased) individuals. The initial collection of stool metagenomes consisted of 12957 samples from 73 independent studies. All raw metagenome samples (.fastq files) were downloaded and reprocessed uniformly using identical bioinformatics methods. After quality control of sequenced reads, taxonomic profiling was performed using MetaPhlAn3. Studies and samples were removed based on several exclusion criteria. Finally, a total of 8069 samples (5547 and 2522 metagenomes from healthy and non-healthy individuals, respectively) from 54 studies ranging across healthy and 11 non-healthy phenotypes were assembled into a pooled metagenome dataset for downstream analyses. b Demographic summary of the study subjects whose metagenome samples were included in the pooled dataset. Subject demographics, as reported in the original studies, include country of origin (n = 8069), age (n = 4670), and sex (n = 5247).
Fig. 1 Conducting a pooled analysis of stool metagenomes across multiple health and disease conditions from a diverse global representation. a A survey was conducted in PubMed and Google Scholar to search for published studies with publicly available human stool shotgun metagenome (gut microbiome) samples from healthy (disease-free) and non-healthy (diseased) individuals. The initial collection of stool metagenomes consisted of 12957 samples from 73 independent studies. All raw metagenome samples (.fastq files) were downloaded and reprocessed uniformly using identical bioinformatics methods. After quality control of sequenced reads, taxonomic profiling was performed using MetaPhlAn3. Studies and samples were removed based on several exclusion criteria. Finally, a total of 8069 samples (5547 and 2522 metagenomes from healthy and non-healthy individuals, respectively) from 54 studies ranging across healthy and 11 non-healthy phenotypes were assembled into a pooled metagenome dataset for downstream analyses. b Demographic summary of the study subjects whose metagenome samples were included in the pooled dataset. Subject demographics, as reported in the original studies, include country of origin (n = 8069), age (n = 4670), and sex (n = 5247).CC BY-NC-ND · PubMed Central
Fig. 2 Gut microbiome taxonomic profiles of healthy and non-healthy individuals inform a Lasso-penalized logistic regression classification model. a Principal component analysis (PCA) of gut microbiome profiles. Significant differences in distributions between healthy (disease-free) (blue, n = 5547) and non-healthy (diseased) (red, n = 2522) groups were observed (P < 0.05, PERMANOVA). Ellipses represent 95% confidence regions. The loading vectors with the top 10 highest PC1 and PC2 magnitudes are shown. b Coefficient values for the Lasso-penalized logistic regression model. The model includes 49 taxa with positive coefficients, 3105 taxa with zero coefficients, and 46 taxa with negative coefficients.
Fig. 2 Gut microbiome taxonomic profiles of healthy and non-healthy individuals inform a Lasso-penalized logistic regression classification model. a Principal component analysis (PCA) of gut microbiome profiles. Significant differences in distributions between healthy (disease-free) (blue, n = 5547) and non-healthy (diseased) (red, n = 2522) groups were observed (P < 0.05, PERMANOVA). Ellipses represent 95% confidence regions. The loading vectors with the top 10 highest PC1 and PC2 magnitudes are shown. b Coefficient values for the Lasso-penalized logistic regression model. The model includes 49 taxa with positive coefficients, 3105 taxa with zero coefficients, and 46 taxa with negative coefficients.CC BY-NC-ND · PubMed Central
Fig. 3 Enhanced classification of healthy and non-healthy stool metagenomes using Gut Microbiome Wellness Index 2 (GMWI2). a GMWI2 best stratifies healthy (n = 5547) and non-healthy (n = 2522) groups compared to GMWI and α-diversity indices (P-values from the two-sided Mann–Whitney U test; d, Cliff’s Delta effect size). Balanced accuracies on the training set are shown for GMWI2 and GMWI. b The healthy group (blue, far left) exhibits significantly higher GMWI2 scores than all 11 non-healthy phenotypes (P-values from the two-sided Mann–Whitney U test). Non-healthy phenotypes include multiple sclerosis (MS, n = 24), ankylosing spondylitis (AS, n = 95), rheumatoid arthritis (RA, n = 151), ulcerative colitis (UC, n = 250), nonalcoholic fatty liver disease (NAFLD, n = 86), type 2 diabetes (T2D, n = 377), Crohn’s disease (CD, n = 284), Graves’ disease (GD, n = 100), colorectal cancer (CC, n = 789), liver cirrhosis (LC, n = 152), and atherosclerotic cardiovascular disease (ACVD, n = 214). c Bins of GMWI2 and GMWI scores (x-axis). The height of the black and gray bars indicate metagenome sample counts in each GMWI2 and GMWI bin, respectively (y-axis, left). Points represent the proportion of samples in each GMWI2 or GMWI bin corresponding to actual healthy and non-healthy individuals (y-axis, right). d Increased magnitude cutoffs result in improved classification performance of GMWI2, showing increasing training set balanced accuracy (blue, y-axis, left) at the expense of decreasing retained samples (orange, y-axis, right). e Classification performances of GMWI and GMWI2 in distinguishing healthy and non-healthy groups. Accuracies (y-axis, left) are depicted for both groups on the training set, leave-one-out cross-validation (LOOCV), and 10-fold CV, using varying magnitude cutoffs (0, 0.5, 1.0) of GMWI and GMWI2 scores. Balanced accuracies are shown between the blue and pink bars, which represent healthy and non-healthy groups, respectively. Orange points represent the proportion of retained samples (y-axis, right) for the corresponding index magnitude cutoff. For 10-fold CV, repeated random sub-sampling was performed ten times, and the average results are displayed. Standard box-and-whisker plots (i.e., center line, median; box limits, upper and lower quartiles; whiskers, 1.5× interquartile range; points, outliers) are used to depict groups of numerical data in (a, b).
Fig. 3 Enhanced classification of healthy and non-healthy stool metagenomes using Gut Microbiome Wellness Index 2 (GMWI2). a GMWI2 best stratifies healthy (n = 5547) and non-healthy (n = 2522) groups compared to GMWI and α-diversity indices (P-values from the two-sided Mann–Whitney U test; d, Cliff’s Delta effect size). Balanced accuracies on the training set are shown for GMWI2 and GMWI. b The healthy group (blue, far left) exhibits significantly higher GMWI2 scores than all 11 non-healthy phenotypes (P-values from the two-sided Mann–Whitney U test). Non-healthy phenotypes include multiple sclerosis (MS, n = 24), ankylosing spondylitis (AS, n = 95), rheumatoid arthritis (RA, n = 151), ulcerative colitis (UC, n = 250), nonalcoholic fatty liver disease (NAFLD, n = 86), type 2 diabetes (T2D, n = 377), Crohn’s disease (CD, n = 284), Graves’ disease (GD, n = 100), colorectal cancer (CC, n = 789), liver cirrhosis (LC, n = 152), and atherosclerotic cardiovascular disease (ACVD, n = 214). c Bins of GMWI2 and GMWI scores (x-axis). The height of the black and gray bars indicate metagenome sample counts in each GMWI2 and GMWI bin, respectively (y-axis, left). Points represent the proportion of samples in each GMWI2 or GMWI bin corresponding to actual healthy and non-healthy individuals (y-axis, right). d Increased magnitude cutoffs result in improved classification performance of GMWI2, showing increasing training set balanced accuracy (blue, y-axis, left) at the expense of decreasing retained samples (orange, y-axis, right). e Classification performances of GMWI and GMWI2 in distinguishing healthy and non-healthy groups. Accuracies (y-axis, left) are depicted for both groups on the training set, leave-one-out cross-validation (LOOCV), and 10-fold CV, using varying magnitude cutoffs (0, 0.5, 1.0) of GMWI and GMWI2 scores. Balanced accuracies are shown between the blue and pink bars, which represent healthy and non-healthy groups, respectively. Orange points represent the proportion of retained samples (y-axis, right) for the corresponding index magnitude cutoff. For 10-fold CV, repeated random sub-sampling was performed ten times, and the average results are displayed. Standard box-and-whisker plots (i.e., center line, median; box limits, upper and lower quartiles; whiskers, 1.5× interquartile range; points, outliers) are used to depict groups of numerical data in (a, b).CC BY-NC-ND · PubMed Central
Fig. 4 Inter-study validation (ISV) shows effective generalization of GMWI2 across diverse study populations. a Classification accuracy on each excluded study in ISV is displayed by gold points (y-axis, right). The studies on the x-axis are rank-ordered based on either accuracy for a single phenotype (healthy or non-healthy) or balanced accuracy in the case of both phenotypes. The stacked bars illustrate the number of healthy (blue) and non-healthy (pink) stool metagenome samples in each study (y-axis, left). b Receiver operating characteristic curves for classification performance in distinguishing healthy and non-healthy phenotypes on the training set, 10-fold CV, and ISV.
Fig. 4 Inter-study validation (ISV) shows effective generalization of GMWI2 across diverse study populations. a Classification accuracy on each excluded study in ISV is displayed by gold points (y-axis, right). The studies on the x-axis are rank-ordered based on either accuracy for a single phenotype (healthy or non-healthy) or balanced accuracy in the case of both phenotypes. The stacked bars illustrate the number of healthy (blue) and non-healthy (pink) stool metagenome samples in each study (y-axis, left). b Receiver operating characteristic curves for classification performance in distinguishing healthy and non-healthy phenotypes on the training set, 10-fold CV, and ISV.CC BY-NC-ND · PubMed Central
Fig. 5 GMWI2 performance on healthy and non-healthy external validation cohorts. a GMWI2 scores from healthy (494 samples) and non-healthy (646 samples) groups. Scores are significantly higher in the healthy group compared to the non-healthy group (P = 1.6 × 10–43; two-sided Mann–Whitney U test). The effect size is represented by Cliff’s Delta (d = 0.48). The balanced accuracy of the classification is 72.1%. b GMWI2 scores across five healthy (H1–H5) and three non-healthy cohorts (AS4 ankylosing spondylitis, PD6 Parkinson’s disease, PC5 pancreatic cancer). The superscript numbers adjacent to phenotype abbreviations correspond to specific studies detailed in Supplementary Data 6. Asterisk (*) indicates significantly higher score in a healthy cohort compared to the corresponding non-healthy cohort (P < 0.01, two-sided Mann–Whitney U test. Exact P-values provided in Supplementary Data 6). Numbers next to each asterisk refer to the healthy cohort compared against each non-healthy condition. Sample size of each group or cohort are shown in parentheses. Standard box-and-whisker plots (i.e., center line, median; box limits, upper and lower quartiles; whiskers, 1.5× interquartile range; points, outliers in (a) or individual GMWI2 scores in (b)) are used to depict groups of numerical data.
Fig. 5 GMWI2 performance on healthy and non-healthy external validation cohorts. a GMWI2 scores from healthy (494 samples) and non-healthy (646 samples) groups. Scores are significantly higher in the healthy group compared to the non-healthy group (P = 1.6 × 10–43; two-sided Mann–Whitney U test). The effect size is represented by Cliff’s Delta (d = 0.48). The balanced accuracy of the classification is 72.1%. b GMWI2 scores across five healthy (H1–H5) and three non-healthy cohorts (AS4 ankylosing spondylitis, PD6 Parkinson’s disease, PC5 pancreatic cancer). The superscript numbers adjacent to phenotype abbreviations correspond to specific studies detailed in Supplementary Data 6. Asterisk (*) indicates significantly higher score in a healthy cohort compared to the corresponding non-healthy cohort (P < 0.01, two-sided Mann–Whitney U test. Exact P-values provided in Supplementary Data 6). Numbers next to each asterisk refer to the healthy cohort compared against each non-healthy condition. Sample size of each group or cohort are shown in parentheses. Standard box-and-whisker plots (i.e., center line, median; box limits, upper and lower quartiles; whiskers, 1.5× interquartile range; points, outliers in (a) or individual GMWI2 scores in (b)) are used to depict groups of numerical data.CC BY-NC-ND · PubMed Central
Fig. 6 Reanalysis of existing longitudinal gut microbiome studies with GMWI2. a Changes in GMWI2 in patients with irritable bowel syndrome observed six months (6-mo) after undergoing fecal microbiota transplantation. Only subjects experiencing symptom relief (“Effect” group) displayed a significant increase in GMWI2 (P = 0.039, one-sided Wilcoxon signed-rank test). n, number of FMT donor samples (17 total samples from two healthy donors) or number of FMT recipients. b GMWI2 scores for dietary groups (EEN, Vegan, and Omnivore) at baseline and at the first 5–6 days of dietary intervention. The EEN group showed significant changes in GMWI2, with values significantly decreased by day 2 and thereafter (P < 0.05, two-sided Wilcoxon signed-rank test). No significant change in GMWI2 was observed for the Omnivore and Vegan groups compared to baseline. n, number of unique individuals who each provided a stool sample per time point. c GMWI2, Shannon Index, and species richness before and after antibiotic intervention. Despite recovery in Shannon Index and species richness at day 42 and day 180, respectively, GMWI2 remained significantly lower compared to day 0, suggesting incomplete gut microbiome recovery even after ~6 months (P < 0.05, two-sided Wilcoxon signed-rank test). n, number of unique individuals who each provided a stool sample per time point. d GMWI2 of gut microbial communities after 24-h in vitro fecal fermentation with five different prebiotic oligosaccharides. The experiment was conducted in triplicates for each study group. The height of the bars represents the mean GMWI2 (numbers inside the solid bars), and error bars indicate the standard deviation from the mean. Points represent individual triplicate samples. Different small letters above the bars denote groups with significant differences in GMWI2 as determined by Tukey’s HSD test (P < 0.05). Control groups: NS0, no substrate addition at 0 h; NS24, no substrate for 24 h. Prebiotic groups: FS24 fructooligosaccharide, IN24 inulin, GS24 galactooligosaccharide, XS24 xylooligosaccharide, FL24 2’-fucosyllactose. Standard box-and-whisker plots (i.e., center line, median; box limits, upper and lower quartiles; whiskers, 1.5× interquartile range; points, individual GMWI2 scores or α-diversity values) are used to depict groups of numerical data in (a–c).
Fig. 6 Reanalysis of existing longitudinal gut microbiome studies with GMWI2. a Changes in GMWI2 in patients with irritable bowel syndrome observed six months (6-mo) after undergoing fecal microbiota transplantation. Only subjects experiencing symptom relief (“Effect” group) displayed a significant increase in GMWI2 (P = 0.039, one-sided Wilcoxon signed-rank test). n, number of FMT donor samples (17 total samples from two healthy donors) or number of FMT recipients. b GMWI2 scores for dietary groups (EEN, Vegan, and Omnivore) at baseline and at the first 5–6 days of dietary intervention. The EEN group showed significant changes in GMWI2, with values significantly decreased by day 2 and thereafter (P < 0.05, two-sided Wilcoxon signed-rank test). No significant change in GMWI2 was observed for the Omnivore and Vegan groups compared to baseline. n, number of unique individuals who each provided a stool sample per time point. c GMWI2, Shannon Index, and species richness before and after antibiotic intervention. Despite recovery in Shannon Index and species richness at day 42 and day 180, respectively, GMWI2 remained significantly lower compared to day 0, suggesting incomplete gut microbiome recovery even after ~6 months (P < 0.05, two-sided Wilcoxon signed-rank test). n, number of unique individuals who each provided a stool sample per time point. d GMWI2 of gut microbial communities after 24-h in vitro fecal fermentation with five different prebiotic oligosaccharides. The experiment was conducted in triplicates for each study group. The height of the bars represents the mean GMWI2 (numbers inside the solid bars), and error bars indicate the standard deviation from the mean. Points represent individual triplicate samples. Different small letters above the bars denote groups with significant differences in GMWI2 as determined by Tukey’s HSD test (P < 0.05). Control groups: NS0, no substrate addition at 0 h; NS24, no substrate for 24 h. Prebiotic groups: FS24 fructooligosaccharide, IN24 inulin, GS24 galactooligosaccharide, XS24 xylooligosaccharide, FL24 2’-fucosyllactose. Standard box-and-whisker plots (i.e., center line, median; box limits, upper and lower quartiles; whiskers, 1.5× interquartile range; points, individual GMWI2 scores or α-diversity values) are used to depict groups of numerical data in (a–c).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 50

Metadata

Authors
Chang, D., Gupta, V. K., Hur, B., Cobo-López, S., Cunningham, K. Y., Han, N. S., Lee, I., Kronzer, V. L., Teigen, L. M., Karnatovskaia, L. V., Longbrake, E. E., Davis, J. M., Nelson, H., & Sung, J.
Affiliations
  • University of Minnesota (US)
  • Mayo Clinic (US)
  • San Diego State University (US)
  • Chungbuk National University (KR)
  • Yonsei University (KR)
  • Yale University (US)
Corresponding author
Sung, Jaeyun
Venue
Nature Communications
Published
2024-08-28
Volume
15
Issue
1
Pages
7447-7447
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4401945686
Cited by
50
References
51
Citations by year
2026: 26 · 2025: 23 · 2024: 1
FWCI
6.81
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (publishedVersion)
Funders
  • U.S. Department of Health & Human Services | National Institutes of Health (UL1TR002377)
  • Minnesota Partnership for Biotechnology and Medical Genomics Center for Individualized Medicine, Mayo Clinic
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
  • Physical Sciences › Environmental Science › Ecology › Microbial Community Ecology and Physiology
Keywords
gut microbiota, health prediction, disease prediction, stool metagenomics, alpha diversity, external validation, antibiotic exposure, fecal microbiota transplantation, open source tools
MeSH terms
Gastrointestinal Microbiome, Bacteria, Feces, Female, Health Status, Humans, Metagenome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gut Microbiome Wellness Index 2 enhances health status prediction from gut microbiome taxonomic profiles. https://app.cochat.ai/papers/10.1038/s41467-024-51651-9
The paper
Chang, D., Gupta, V. K., Hur, B., Cobo-López, S., Cunningham, K. Y., Han, N. S., Lee, I., Kronzer, V. L., Teigen, L. M., Karnatovskaia, L. V., Longbrake, E. E., Davis, J. M., Nelson, H., & Sung, J. (2024). Gut Microbiome Wellness Index 2 enhances health status prediction from gut microbiome taxonomic profiles. Nature Communications. https://doi.org/10.1038/s41467-024-51651-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.